Effects of a three-month course of rosuvastatin in patients with Systemic Lupus Erythematosus

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN63412511

Enrollment

Registered

2008-03-26

Start date

2005-01-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Systemic lupus erythematosus Musculoskeletal Diseases Systemic lupus erythematosus

Interventions

Rosuvastatin 10 mg once daily.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients with chronic, non-acute SLE 2. Greater than 18 years old, either sex

Exclusion criteria

Exclusion criteria: 1. Use of statins 2. Pregnancy 3. Raised liver enzymes 4. Recent (less than three months) major surgery or myocardial infarction

Design outcomes

Primary

Measure	Time frame
Measured at baseline and after three months of treatment: 1. Total cholesterol 2. Low density lipoprotein (LDL) cholesterol 3. C-reactive protein (CRP) 4. Tumour necrotising factor (TNF)	—

Secondary

Measure	Time frame
Measured at baseline and after three months of treatment: 1. Interleukin-6 (IL6), interleukin-10 (IL10), interleukin-8 (IL8) 2. Complement C3 and C4q 3. Anti-double stranded deoxyribonucleic acid (anti-dsDNA) 4. Urine protein	—

Countries

Netherlands

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026